US 12,351,566 B2
MEK inhibitors and therapeutic uses thereof
Brett Matthew Hall, San Diego, CA (US); Bart Lieven Decorte, Southampton, PA (US); Peter John King, San Diego, CA (US); Ruben Leenders, Cambridge, MA (US); Anita Wegert, Cambridge, MA (US); Kevin Fowler, Cambridge, MA (US); Sarah Kolitz, Cambridge, MA (US); Robin Doodeman, Cambridge, MA (US); Jarno Poelakker, Cambridge, MA (US); and Rutger Henk Adriaan Folmer, Cambridge, MA (US)
Assigned to Immuneering Corporation, Cambridge, MA (US)
Appl. No. 17/791,755
Filed by Immuneering Corporation, Cambridge, MA (US)
PCT Filed Jan. 7, 2021, PCT No. PCT/US2021/012531
§ 371(c)(1), (2) Date Jul. 8, 2022,
PCT Pub. No. WO2021/142144, PCT Pub. Date Jul. 15, 2021.
Claims priority of provisional application 62/959,732, filed on Jan. 10, 2020.
Prior Publication US 2023/0119327 A1, Apr. 20, 2023
Int. Cl. C07D 311/06 (2006.01); A61P 35/00 (2006.01); C07D 405/12 (2006.01); C07D 407/12 (2006.01); C07D 409/12 (2006.01)
CPC C07D 311/06 (2013.01) [A61P 35/00 (2018.01); C07D 405/12 (2013.01); C07D 407/12 (2013.01); C07D 409/12 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A compound of Formula (IIb):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
Z is C or N;
R2 is L;
L is —Z1—Z2;
Z1 is —CH2—;
Z2 is —NR5R5′;
each of R5 and R5′ are each independently C1 to C6 alkyl, and
R6 is H, deuterium, halogen, or C1 to C6 alkyl.